There are hardly any drugs against ALS. A new study shows that a substance acting on the MAPK signaling pathway may be effective against the neurodegenerative disease: After treatment with trametinib, ...

Pictured are nuclei of induced pluripotent stem cell (iPSC)-derived motor neurons stained for contrast. The nucleus on the left has been treated with DMSO (control) and appears mostly blue. The ...

Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for ...

Clene (CLNN) announced that it recently received written guidance from the Division of Neurology 1, DN1, of the U.S. Food and Drug Administration regarding a potential accelerated approval pathway for ...

When brain cells die in diseases like ALS (amyotrophic lateral sclerosis) and frontotemporal dementia, they often activate a ...